Ultragenyx Pharmaceutical Inc. - COM (RARE)

Historical Portfolio Holders from Q1 2014 to Q1 2024

All holders as of March 31, 2024
Q1 2024
Type / Class
Equity / COM
Shares, excl. options Q1 2024
78.2 M
Holdings value Q1 2024
$3.65 B
Value change Q1 2024
-$59.6 M
Grand Portfolio weight change Q1 2024
0%
Number of holders
258
Number of buys Q1 2024
144
Number of sells Q1 2024
-94
Average buys Q1 2024 %
+0.002%
Average sells Q1 2024 %
-0.001%
CUSIP
90400D108
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Period Shares, Excl. Options Value, Excl. Options Change Price Investors
2024 Q1 78.2 M $3.65 B -$59.6 M $46.69 258
2023 Q4 79.6 M $3.81 B +$495 M $47.82 233
2023 Q3 69.6 M $2.48 B +$11.1 M $35.65 216
2023 Q2 68.6 M $3.16 B +$15.1 M $46.13 233
2023 Q1 68.5 M $2.75 B +$26.1 M $40.10 223
2022 Q4 67.9 M $3.14 B +$17.2 M $46.33 219
2022 Q3 61.4 M $2.54 B -$145 M $41.41 213
2022 Q2 62.1 M $3.7 B +$18.6 M $59.66 201
2022 Q1 61.7 M $4.48 B -$41.8 M $72.62 217
2021 Q4 67.3 M $5.66 B +$82 M $84.09 215
2021 Q3 66.6 M $6.01 B +$102 M $90.19 212
2021 Q2 65.4 M $6.23 B -$249 M $95.35 230
2021 Q1 67.8 M $7.72 B +$50 M $113.86 251
2020 Q4 67.5 M $9.35 B +$639 M $138.43 244
2020 Q3 63 M $5.18 B -$1.95 M $82.19 194
2020 Q2 63.1 M $4.94 B +$248 M $78.22 183
2020 Q1 59.9 M $2.66 B +$85.6 M $44.43 161
2019 Q4 55.2 M $2.36 B -$33.6 M $42.71 159
2019 Q3 55.7 M $2.38 B -$47.5 M $42.78 154
2019 Q2 58.7 M $3.73 B +$71.7 M $63.50 158
2019 Q1 58 M $4.02 B +$543 M $69.36 168
2018 Q4 50.5 M $2.2 B -$8.89 M $43.48 152
2018 Q3 49.7 M $3.8 B +$72.5 M $76.34 167
2018 Q2 48.8 M $3.75 B +$80.2 M $76.87 148
2018 Q1 48.9 M $2.49 B +$367 M $50.99 157
2017 Q4 43.2 M $2 B +$107 M $46.38 154
2017 Q3 40.6 M $2.16 B -$37 M $53.26 147
2017 Q2 41 M $2.54 B +$29.5 M $62.11 152
2017 Q1 40.5 M $2.74 B +$147 M $67.78 158
2016 Q4 41.2 M $2.9 B +$149 M $70.31 168
2016 Q3 39.5 M $2.8 B +$185 M $70.94 167
2016 Q2 36.4 M $1.78 B -$45.3 M $48.91 154
2016 Q1 36.5 M $2.31 B +$79.8 M $63.31 153
2015 Q4 35.6 M $3.99 B +$41.3 M $112.18 163
2015 Q3 34.9 M $3.36 B +$212 M $96.31 154
2015 Q2 32.2 M $3.3 B +$99.9 M $102.39 147
2015 Q1 31.6 M $1.96 B +$230 M $62.09 124
2014 Q4 27.9 M $1.23 B +$58.8 M $43.88 99
2014 Q3 26.4 M $1.5 B +$358 M $56.60 98
2014 Q2 15.6 M $690 M +$13.8 M $44.89 80
2014 Q1 15.3 M $730 M +$730 M $48.89 76